On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study

Active, not recruitingOBSERVATIONAL
Enrollment

510

Participants

Timeline

Start Date

November 10, 2015

Primary Completion Date

April 30, 2027

Study Completion Date

August 31, 2027

Conditions
Thrombotic and Bleeding Events
Interventions
DEVICE

On-X Aortic Heart Valve replacement

Aortic valve replacement with low dose warfarin

Trial Locations (23)

23507

Sentara Norfolk General Hospital, Norfolk

24014

Carilion Clinic, Roanoke

44195

Cleveland Clinic, Cleveland

45219

The Lindner Center at The Christ Hospital, Cincinnati

46237

Franciscan St. Francis, Indianapolis

58122

Sanford Medical Center, Fargo

75093

Baylor Scott & White - Plano, Plano

75390

University of Texas Southwestern, Dallas

77030

University of Texas Health Science Center - Houston, Houston

85718

Arizona Cardiothoracic & Neurology, Tucson

97213

Providence St. Vincent, Portland

98122

Swedish Medical Center, Seattle

98405

MultiCare Health System, Tacoma

06102

Hartford Hospital, Hartford

04102

Maine Medical Center, Portland

Unknown

University of Calgary, Calgary

Victoria Heart Institute, Victoria

Blackpool Victoria Hospital, Blackpool

Hull & East Yorkshire Hospitals, Hull

John Radcliffe Hospital, Oxford

K1Y 4W7

University of Ottawa Heart Institute, Ottawa

EC1A 7BE

St. Bartholomew's Hospital, London

SO16 6YD

University Hospital Southampton, Southampton

Sponsors
All Listed Sponsors
collaborator

North American Science Associates Inc.

UNKNOWN

lead

On-X Life Technologies, Inc.

INDUSTRY

NCT02677974 - On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study | Biotech Hunter | Biotech Hunter